Press Releases

UCB and Microsoft have announced a new multi-year, strategic collaboration to combine Microsoft's computational services, cloud, and artificial intelligence (AI) with UCB's drug discovery and development capabilities. As several drug discovery activities require the analysis of high-dimensional data sets or multi-modal unstructured information, Microsoft's platform can support UCB's scientists, including its data scientists, to discover new medicines in a more efficient and in

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced that the Company has acquired an exclusive license from Alexion Pharmaceuticals to certain patent-pending inventions relating to nucleic acid purification technologies. Since the Company’s inception in 2013, Arcturus has been building proprietar

Celldex Therapeutics, Inc. announced that the Company will expand clinical development of CDX-0159 into prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin. Mast cells through their interactions with sensory neurons and other immune cells are believed to play an important role in amplifying chronic itch and neuroinflammation, both of which are a hallmark of PN. CDX-0159 is a humanized monoclonal antibody devel

BioVaxys Technology Corp. announced that there is a Termsheet ("Termsheet") with BioElpida SAS ("BioElpida") based in Lyon , France has signed to collaborate on setting up the clinical manufacturing process and aseptic packaging for BXV-0918A, BioVaxy's vaccine against Stage III / Stage IV ovarian cancer. The completion of the development of the GMP-compliant organic production process is planned for this year. The EU phase I / II clinical trial is scheduled for early

ImmunoPrecise Antibodies Ltd. announced preliminary, preclinical data in hamsters of IPA’s proprietary TATX-03 PolyTope antibody cocktail program against SARS-CoV-2, the virus that causes COVID-19 disease. In a preclinical study using a SARS-CoV-2 hamster model, treatment with IPA’s TATX-03 resulted in complete clearance of detectable replication-competent virus from the lungs and throat of SARS-CoV-2 infected animals. The results of the preclinical study demonstrated th

Metabolon, Inc. has entered into to a multi-year collaborative agreement with Cleveland Clinic to provide Metabolon's Precision Metabolomics™ services in support of drug development and related research efforts. Metabolon will leverage its proprietary platform to analyze a range of biologic samples to help discover metabolomic biomarkers that will deepen understanding of Cleveland Clinic's novel discoveries, improve speed of decision-making and accelerate clinical trials.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced agreements with Cosmo Pharmaceuticals NV (SIX: COPN) ("Cosmo") to manufacture two key products; RedHill's largest selling product in the U.S., Movantik®, and RHB-204, currently in a Phase 3 U.S. study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease. "Movantik is currently our biggest commercial product. This agreement stre

Maculus Therapeutix, a preclinical-stage biopharmaceutical company which has developed a SINGLE injection delivery platform for diseases such as wet AMD (Age-related Macular Degeneration) and DME (Diabetic Macular Edema) instead of the standard 8-12 monthly injections, is pleased to welcome Privity FZ LLE as a partner and advisor for upcoming fundraising activities. Maculus plans to raise USD3 million on a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studi

SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, 3692:HK), one of the leading biopharmaceutical companies in China, announced a strategic partnership and license agreement for the development and commercialization of Ibrexafungerp for the Greater China region. Ibrexafungerp is a first-in-class, broad-spectrum t

Nektar Therapeutics, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cancer and auto-immune disease, today announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin (BEMPEG), an investigational CD122-preferential IL-2–pathway agonist. SFJ Pharmaceuticals is a global drug development company backed by Abingworth and Blackstone Life Sciences. T